Drug companies favour these "golden tracks" in the wake of the innovation drug explosion

"Pharmaceutical Network Industry Dynamics" After years of hard work, China's innovative drugs have begun to achieve greater development.
data show that from 2007 to the first half of 2019, the number of domestic enterprises reporting clinical trials or production of innovative drugs has reached 700, with hundreds of innovative drugs.
, the domestic innovative drug market capacity is also expanding, in the past 6 years, the compound growth rate of innovative drugs has reached 27%.
, after years of research and development investment, the results have been initially apparent, the domestic innovative pharmaceutical industry began to enter a new stage.
, but it is worth noting that in the pharmaceutical companies have laid out innovative drugs under the general trend, there are three tracks are increasingly favored by pharmaceutical companies, there has been a pile of research and development.
anti-tumor drugs in recent years, the development of innovative drugs for the PD-1/PD-L1 market can be said to be very hot.
data show that there are currently more than 2,000 cancer treatment drugs and vaccines in different stages of research and development, more than 90% of targeted drugs.
in China, as early as 2018, there are about 20 domestic PD-(L)1 single resistance in research and development, research and development of pharmaceutical companies including Junshi Biological, Xinda Bio and Hengrui Medicine.
addition, in the first half of 2019, CDE hosted 145 newly declared chemical drugs in the field of new drugs, anti-tumor drug declared varieties also have 60, far more than the second-ranked neurological drugs (23 varieties).
and the reason why pharmaceutical companies have such a large enthusiasm for research and development, mainly based on the huge clinical needs of anti-tumor drugs.
industry estimates that the global cancer drug market will exceed $150 billion by 2020 and that sales of prescription cancer drugs will exceed $110 billion.
huge market demand, coupled with China's drug review and approval reform, to encourage drug innovation, pharmaceutical companies pile up the layout of anti-tumor drugs can be imagined.
However, it should be noted that although more and more enterprises to join the competition, but the entry threshold of PD-1 is not low, the research and development strength requirements are quite high, and the cost of investment is huge, the industry suggested that the strength of enterprises or do not rush into.
the field of chronic diseases, China's elderly population has exceeded 200 million people, with the aging of the economic burden brought about by chronic diseases is further increased.
data show that china's chronic disease-related deaths have accounted for 85% of the total deaths, resulting in the burden of disease has accounted for 70% of the total burden of disease.
, in the chain of slow disease management, prevention, early screening, medication, control and other links are indispensable.
, China's huge slow-disease market is also attracting many pharmaceutical companies to speed up the layout.
E., at the end of May last year, Pfizer opened its global headquarters in Shanghai for non-communicable diseases, including cardiovascular, pain and neurological, mental, urinary and ophthalmological diseases, the first global headquarters of a multinational pharmaceutical company in China.
In addition, as early as 2014, Shi Pharmaceutical Group's innovative drug "Hyunning" launched the U.S. NDA project, December 20, 2019, by the U.S. Food and Drug Administration review and approval, becoming the first chinese companies to obtain full U.S. approval of innovative drugs.
, in the chain of chronic disease management, will certainly give birth to a series of huge business opportunities, in order to win more markets, pharmaceutical companies need to be laid out as soon as possible.
years, the resonance of multiple positive factors is pushing China's vaccine industry into a golden period of development.
regulatory level, the landing of vaccine management law from the legislative height, promote the vaccine industry to further standardize, innovation and intensive development.
second, China's vaccine industry has entered the era of domestic large varieties, domestic 13-price pneumonia vaccine, 2-price hpv vaccine and other large varieties are also promoting the continued expansion of the vaccine industry.
, the development of the vaccine industry as a whole is optimistic, many enterprises are also increasing the layout of this area.
As tibet Pharmaceuticals announced on June 15 this year, it will cooperate with Sri Microbiology to invest 351 million yuan in the development, registration, production, use and commercialization of the vaccine.
Consino is an innovative vaccine company dedicated to vaccine development, production and marketing.
in recent years, we have also been rapidly promoting the development of a series of innovative vaccines in China, including a large number of clinically inoculated heavy vaccines against meningitis, white-cracking, pneumonia, tuberculosis, shingles and other adaptations.